Given its pivotal role in the remyelination process, the migration, differentiation, and death of OPCs have long been determined to be crucial factors in MS pathogenesis and therapeutic targets of MS. Inflammation-independent progressive nerve degeneration has been observed in all three types of MS19, and a pronounced loss of oligodendrocyte was noted at the center of demyelinated lesions20, suggesting that primary disorders of oligodendrocyte lineage cells could accelerate the progression of MS.
In this study, we performed a bioinformatics analysis of targeted mRNA sequences focusing on genes associated with ferroptosis and hypoxia in iPSC-induced OPCs from PwMS and healthy controls via merged datasets from four healthy controls and nine PwMS. We discovered 706 DEGs, 378 of which were upregulated and 328 of which were downregulated. We further identified ferroptosis- and hypoxia-related genes and compared their expression in the iPSC-induced OPCs of MS patients and healthy controls by calculating the Z score of each sample. The Z scores of ferroptosis and hypoxia were significantly greater in PwMS than in healthy controls.
Hypoxia plays a significant role in oligodendrogliopathy in MS. Pathological studies have demonstrated distal oligodendrogliopathy in type III MS lesions resembling ischemic white matter stroke16 as well as hypoxic-like injuries alongside elevated ROS and NO levels in acute MS lesions21. Disruption of mitochondrial respiratory chain complex IV impairs the formation and viability of OPCs and mature oligodendrocytes15, although the exact mechanisms underlying this impairment remain to be elucidated.
Additionally, ferroptosis, an iron-dependent form of programmed cell death, has been found to mediate the loss of oligodendrocytes and the progression of demyelination in cuprizone-induced MS animal models22. Single-cell sequencing has revealed a decrease in antiferroptosis gene expression in OPCs and OLs in brain tissue from PwMS23. In the chronic phase of MS, iron deficiency in oligodendrocytes can disrupt remyelination and compromise axonal integrity in the white matter, resulting in disease progression24. Moreover, snRNA-seq of MS lesions in white matter suggests that ferroptosis is mostly active in white matter lesions of MS patients and is associated with activation of the phagocyte system25. In experimental autoimmune encephalomyelitis (EAE) mice, the levels of GPX4, an important regulator of ferroptosis, are reduced26. The disease progression of EAE can be accelerated by ferroptosis induced by ACSL4, which enhances T-cell receptor (TCR) signaling. Blocking ferroptosis and ACSL4 significantly slows disability progression in EAE27.
Ferroptosis is involved in the cognitive decline caused by hypoxia in rat models28. Hypoxia and hypoxia-inducible factor-1α promote the proliferation and migration of dorsal root ganglia29. Thus, ferroptosis and hypoxia may act synergistically in the pathogenesis of MS. Through WGCNA, our study identified two significant modules; the turquoise module, in particular, was strongly correlated with MS status, hypoxia, and ferroptosis. Based on the results of the WGCNA and DEGs, we identified 71 key genes that were simultaneously correlated with ferroptosis, hypoxia and MS.
GO and KEGG functional enrichment analyses of the 706 DEGs revealed that the PI3K-Akt signaling pathway is a crucial pathway in MS development. The inhibition of CXCR2 enhances OPC differentiation and promotes remyelination in MS mouse models by activating PI3K/AKT/mTOR signaling30. An imbalance in oxygen supply could affect the MAPK/PI3K-Akt signaling pathways, triggering key mechanisms involved in oxidative stress31.
PPI analysis revealed that 10 hub genes, namely, COL4A1, COL4A2, ITGB5, ITGB1, ITGB8, ITGAV, VIM, FLNA, VCL, and SPARC, were simultaneously correlated with hypoxia, ferroptosis, and MS, with notable overexpression in MS patients compared with controls. These genes were further validated in GSE151306, a database of iPSC-induced OPC lines derived from SPMS patients. We found that ITGAV, ITGB8, and VIM were also upregulated in the validation set. In Particular, ITGB8—part of the integrin family—was significantly overexpressed in MS, which was consistent with the combined test sets GSE147315 and GSE196575.
The gene ITGB8 is a member of the integrin (ITG) family and encodes integrin beta 8, which has been previously reported to be a regulator of tumor growth and metastasis32,33. Integrin beta 8 is strongly expressed by OPCs and mature oligodendrocytes. One study showed that osteopontin protects OPCs from H2O2-induced apoptosis by upregulating integrins, including ITGB834. These findings indicates that ITGB8 plays a role in cell survival under oxidative stress conditions. In multiple sclerosis, where oxidative stress is prevalent, ITGB8 may help OPCs survive and differentiate into oligodendrocytes to increase remyelination.
ITGAV encodes the integrin subunit alpha V, which regulates angiogenesis and cancer progression. ITGAV, in combination with beta 5 (forming integrin αvβ5), mediates microglial activation in response to fibronectin and vitronectin deposition, which are elevated in MS lesions. In the MS rat model of EAE, integrin avβ5 activated microglia, leading to increased expression of matrix metalloproteinase-9 (MMP-9), an enzyme that degrades the extracellular matrix and myelin proteins, contributing to demyelination35.
Notably, one of the hub genes that was differentially expressed in our merged set, ITGB1, was found to be upregulated in CD4+ T cells extracted from the cerebrospinal fluid of MS patients36. Integrin β1 had a notable effect on the PI3K-Akt signaling pathway, which is consistent with our findings (Figure 11)37. Moreover, increased expression of β1-integrin was detected on Th17 cells in MS patients compared with healthy controls. The activation of β1-integrin in Th17 cells can significantly increase glutamate levels and promote neuroinflammation38.
We conducted ROC curve analysis to assess the potential of ITGAV, ITGB8, and VIM expression in OPCs as biomarkers for MS risk prediction. The AUC of ITGB8 was 100%, followed by 91.7% for VIM and 58.3% for ITGAV. Currently, there are no studies reporting the association of the expression of ITGB8 in oligodendrocytes with MS. Further studies should be conducted to explore the use of ITGB8 as a biomarker for the prediction of MS.
Finally, we constructed a transcription factor-hub gene network and identified three key transcription factors: HOXD3, SP1, and VHL. SP1 is a transcription factor that binds to many promoters. SP1, known for its broad promoter binding, has been shown to regulate Prdx6 expression, inhibit ROS, and eliminate ferroptosis in high-glucose environments39. The expression of SP1 has also been linked to tumor necrosis factor (TNF) activity, which plays a crucial role in the development of RRMS40. The androgen receptor (AR), another identified transcription factor, is activated by steroid hormones and is detected in astrocytes within the remyelination zones, highlighting its potential involvement in oligodendrocyte function41.
Immune pathways and cells play important roles in the pathogenesis and neurodegeneration of MS and are possibly associated with ferroptosis, hypoxia, and OPCs. Observations from cuprizone-intoxicated mice as well as progressive MS lesions have shown high prevalence and proliferation rates of CD8+ T cells with cytotoxic granule overexpression42. Sufficiently activated T cells are capable of interacting with antigen-presenting oligodendrocytes, potentially leading to CD8+ T-cell-mediated oligodendrocyte destruction. In the tumor microenvironment, interferon-γ secreted by CD8+ T cells reduces the cysteine glutamate exchanger (xCT) expression, enhancing ferroptosis43. Additionally, ferroptosis has been suggested to activate T cells via T-cell receptor signaling in EAE models24.
Current research on OPCs is significantly limited due to the scarcity of these cells. This limitation can be partially addressed by using iPSC-induced OPCs. However, most studies on iPSC-induced OPCs involve small sample sizes, typically fewer than 10 donors, owing to the time-consuming and costly process of cell induction. Our study provides more robust results by integrating samples from multiple studies.
We further refined the bioinformatics pipeline by dividing the available dataset into training and validation sets. This approach minimizes potential biases induced by differences in cell induction methods and sequencing techniques across laboratories. Most existing studies on multiple sclerosis either focus on inflammation-driven neurodegeneration or employ isolated analysis of ferroptosis. Traditional gene expression analyses are useful for identifying individual differentially expressed genes but often fail to reveal the complex interaction networks and coexpression patterns associated with MS progression. In contrast, our methodology leverages WGCNA to construct a gene coexpression network, enabling the identification of gene modules highly correlated with both ferroptosis and hypoxia. This provides a system-level understanding of how these pathways interact within MS pathology, which is not achievable with standard differential expression methods alone.
This method can be applied to new treatments for MS by identifying gene targets for therapies aimed at reducing neurodegeneration. It could also be used in other neurodegenerative diseases involving ferroptosis and hypoxia, such as Parkinson's or Alzheimer's disease, to develop tailored interventions and predict therapeutic responses.
Our research has several limitations. First, further in vivo and in vitro validation is necessary. Second, our results are from two databases and were validated in one database covering a limited number of patients. Larger cohorts should be collected for further exploration. Third, considering the difficulty in accessing to human OPCs, the database we adopted was based on iPSC-induced OPCs, which may not fully resemble human tissue. More studies focused on investigating the impact of hypoxia and ferroptosis on the differentiation and cell death of oligodendrocytes lineage cells in MS should be carried out in the future.
Another limitation of this study is the inability to analyze immune cell interactions due to the use of OPCs derived from iPSCs, which lack the immune cells present in MS lesions. While immune cells are crucial in MS pathogenesis, this limitation reflects the challenges of using iPSC-derived cultures. Future studies should focus on OPC-immune cell crosstalk through coculture systems or organoids, which can better model cellular interactions in the MS environment.